Matthew Lunning, DO, presents a case of a 71-year-old woman with relapsed/refractory diffuse large B-cell lymphoma and discusses considerations for therapy.
A 71-Year-Old Woman with Relapsed/Refractory DLBCL
DLBCL expert Matthew Lunning, DO, describes risk assessment in patients with DLBCL and how it informs first-line treatment choice.
Dr Matthew Lunning reviews second-line treatment options for patients with R/R DLBCL and provides insight on individualizing therapy.
Matthew Lunning, DO, presents the efficacy and safety findings of the L-MIND trial in relapsed/refractory diffuse large B-cell lymphoma and discusses the implications for clinical practice.
Dr Lunning reviews potential options for later line therapy for patients with R/R DLBCL and shares his thought about future directions in the evolving treatment landscape.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
